Electronic Journal of Liver Tumor ›› 2023, Vol. 10 ›› Issue (3): 12-26.
• Observing reveals the intricate-talk to chief-editor • Previous Articles Next Articles
Received:2023-08-18
Online:2023-09-30
Published:2023-10-25
| [1] KENNEDY L B, SALAMA A K S. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020,70(2):86-104. [2] GARON E B, RIZVI N A, HUI R, et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015,372(21):2018-2028. [3] ANTONIA S J, BORGHAEI H, RAMALINGAM S S, et al.Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis[J]. Lancet Oncol, 2019,20(10):1395-1408. [4] ROBERT C, RIBAS A, SCHACHTER J, et al.Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019,20(9):1239-1251. [5] ASCIERTO P A, DEL VECCHIO M, MANDALÁ M, et al.Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020,21(11):1465-1477. [6] EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. [7] CHENG A L, QIN S, IKEDA M, et al.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022,76(4):862-873. [8] ZHU AX, FINN RS, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952. [9] FINN R S, IKEDA M, ZHU A X, et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020,38(26):2960-2970. [10] XU J, SHEN J, GU S, et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial[J]. Clin Cancer Res, 2021,27(4):1003-1011. [11] BENSON A B, D'ANGELICA M I, ABBOTT D E, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021,19(5):541-565. [12] VOGEL A, CERVANTES A, CHAU I, et al.Correction to: "Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up"[J]. Ann Oncol, 2019,30(5):871-873. [13] WANG Y, ZHOU S, YANG F, et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and Meta-analysis[J]. JAMA Oncol, 2019,5(7):1008-1019. [14] ZHOU X, YAO Z, BAI H, et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and Meta-analysis[J]. Lancet Oncol, 2021,22(9):1265-1274. [15] PAGE M J, MCKENZIE J E, BOSSUYT P M, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J]. BMJ, 2021,372:n71. [16] KNAPP G, HARTUNG J.Improved tests for a random effects meta-regression with a single covariate[J]. Stat Med, 2003,22(17):2693-2710. [17] HUNTER J P, SARATZIS A, SUTTON A J, et al.In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias[J]. J Clin Epidemiol, 2014,67(8):897-903. [18] EGGER M, DAVEY-SMITH G, SCHNEIDER M, et al.Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997,315(7109):629-634. [19] STERNE J A C, SAVOVIĆ J, PAGE M J, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials[J]. BMJ, 2019,366:l4898. [20] WELLS G,SHEA B, O’CONNELL D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Meta-analyses[DB/OL]. (2021) [2022-10-18]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [21] VIECHTBAUER W.Conducting meta-analyses in R with the metafor package[J]. J Stat Softw, 2010,36(3):1-48. [22] KUDO M, MATILLA A, SANTORO A, et al.CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol, 2021,75(3):600-609. [23] YAU T, KANG Y K, KIM T Y, et al.Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020,6(11):e204564. [24] KUDO M, FINN R S, EDELINE J, et al.Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J]. Eur J Cancer, 2022,167:1-12. [25] VERSET G, BORBATH I, KARWAL M, et al.Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial[J]. Clin Cancer Res, 2022,28(12):2547-2554. [26] DOI T, MURO K, ISHII H, et al.A Phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors[J]. Clin Cancer Res, 2019,25(22):6614-6622. [27] FEUN L G, LI Y Y, WU C, et al.Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma[J]. Cancer, 2019,125(20):3603-3614. [28] FINN R S, RYOO B Y, MERLE P, et al.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial[J]. J Clin Oncol, 2020,38(3):193-202. [29] BANG Y J, GOLAN T, DAHAN L, et al.Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ)[J]. Eur J Cancer, 2020,137:272-284. [30] LEE M S, RYOO B Y, HSU C H, et al.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020,21(6):808-820. [31] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,382(20):1894-1905. [32] KELLEY R K, SANGRO B, HARRIS W, et al.Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study[J]. J Clin Oncol, 2021,39(27):2991-3001. [33] REN Z, QIN S, MENG Z, et al.A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond first RECIST-Defined progression[J]. Liver Cancer, 2021,10(5):500-509. [34] LI H, QIN S, LIU Y, et al.Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: a sub-cohort of a multicenter phase Ib/II study[J]. Drug Des Devel Ther, 2021,15:1873-1882. [35] KUDO M, MOTOMURA K, WADA Y, et al.Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial[J]. Liver Cancer, 2021,10(3):249-259. [36] LEE D W, CHO E J, LEE J H, et al.Phase II study of avelumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J]. Clin Cancer Res, 2021,27(3):713-718. [37] REN Z, XU J, BAI Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021,22(7):977-990. [38] HAN C, YE S, HU C, et al.Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase Ib/II trial (AK105-203)[J]. Front Oncol, 2021,11:684867. [39] YAU T, PARK J W, FINN R S, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022,23(1):77-90. [40] ZHANG W, GONG C, PENG X, et al.Serum concentration of CD137 and tumor infiltration by M1 macrophages predict the response to sintilimab plus bevacizumab biosimilar in advanced hepatocellular carcinoma patients[J]. Clin Cancer Res, 2022,28(16):3499-3508. [41] ZHENG Y, MISLANG A R A, COWARD J, et al. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers[J]. Cancer Immunol Immunother, 2022,71(10):2371-2379. [42] WU Z, CHEN Q, QU L, et al.Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and Meta-analysis[J]. Eur Urol, 2022,81(4):414-425. [43] YAN Y D, CUI J J, FU J, et al.A network comparison on safety profiling of immune checkpoint inhibitors in advanced lung cancer[J]. Front Immunol, 2021,12:760737. [44] HSU C, RIMASSA L, SUN H C, et al.Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab[J]. Ther Adv Med Oncol, 2021,13:17588359211031141. [45] BANGARU S, MARRERO JA, SINGAL AG.Review article: new therapeutic interventions for advanced hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2020,51(1):78-89. [46] ZHU X, WU S, DAHUT W L, et al.Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis[J]. Am J Kidney Dis, 2007,49(2):186-193. [47] ESTRADA C C, MALDONADO A, MALLIPATTU S K.Therapeutic inhibition of VEGF signaling and associated nephrotoxicities[J]. J Am Soc Nephrol, 2019,30(2):187-200. [48] TABRIZI M A, TSENG C M, ROSKOS L K.Elimination mechanisms of therapeutic monoclonal antibodies[J]. Drug Discov Today, 2006,11(1-2):81-88. [49] SHEN G, ZHENG F, REN D, et al.Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018,11(1):120. [50] HUSSEIN Z, MIZUO H, HAYATO S, et al.Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor[J]. Eur J Drug Metab Pharmacokinet, 2017,42(6):903-914. [51] PEERAPHATDIT T B, WANG J, ODENWALD M A, et al.Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation[J]. Hepatology, 2020,72(1):315-329. [52] CELSA C, GIUFFRIDA P, GIACCHETTO C M, et al.Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma[J]. Liver Cancer Int, 2021,2(3):82-95. [53] SHEMESH CS, CHAN P, SHAO H, et al.Atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma: pharmacokinetic and safety assessments based on hepatic impairment status and geographic region[J]. Liver Cancer, 2021,10(5):485-499. [54] MARUTA S, OGASAWARA S, OOKA Y, et al.Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma[J]. Liver Cancer, 2020,9(4):382-396. [55] UESHIMA K, NISHIDA N, HAGIWARA S, et al.Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study[J]. Cancers (Basel), 2019,11(7):952. [56] VOGEL A, FRENETTE C, SUNG M, et al.Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma[J]. Liver Cancer, 2021,10(5):510-521. [57] ZHOU Y, CHEN C, ZHANG X, et al.Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J]. J Immunother Cancer, 2018,6(1):155. [58] LLOVET J M, KELLEY R K, VILLANUEVA A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021,7(1):6. [59] CHEU J W, WONG C C.Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors[J]. Hepatology, 2021,74(4):2264-2276. [60] ZHANG H, LI Q, ZHU X, et al.Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects[J]. Cancer Chemother Pharmacol, 2018,82(4):615-623. [61] LLOVET JM, CASTET F, HEIKENWALDER M, et al.Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022,19(3):151-172. [62] HUANG A, YANG X R, CHUNG W Y, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020,5(1):146. [63] LISBERG A, TUCKER D A, GOLDMAN J W, et al.Treatment-Related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center[J]. Cancer Immunol Res, 2018,6(3):288-294. [64] PINATO D J, MARRON T U, MISHRA-KALYANI P S, et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice[J]. Eur J Cancer, 2021,157:140-152. [65] HAILEMICHAEL Y, JOHNSON DH, ABDEL-WAHAB N, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity[J]. Cancer Cell, 2022,40(5):509-523.e506. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
